ORYZON to present first in human efficacy data with Vafidemstat at the 27th European Congress of Psychiatry in Warsaw
MADRID, SPAIN and CAMBRIDGE MA.
• Efficacy data from the REIMAGINE Phase IIa basket trial’s Borderline Personality Disorder (BPD) cohort
• Vafidemstat is an active compound in humans
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that the company will be presenting today the first human efficacy data with its CNS epigenetic drug vafidemstat. Specifically, Oryzon is presenting data from its Phase IIa clinical trial REIMAGINE at the 27th European Congress of Psychiatry (EPA 2019) in Warsaw, Poland.